ArticleFrontiers in bioengineering and biotechnology2022
The degradation of gelatin/alginate/fibrin hydrogels is cell type dependent and can be modulated by targeting fibrinolysis.
Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Research Progress on Material, Preparation, Properties, and Water Purification Applications of Solar Energy-Driven Hydrogels.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- hBM-MSC-Laden 3D Bioprinted Gelatin-Alginate Hydrogels: Physicochemical Characterisation and Osteogenic Lineage Commitment.Gels (Basel, Switzerland) · 2026Article
- Strategies to control cellular spatial organization in microphysiological systems.Microsystems & nanoengineering · 2026Review
- Fibrin scaffolds for angiogenesis in soft tissue models: a systematic review.Bioactive materials · 2026Review
- Bioengineered Tricomposite Hydrogel Enhances Chondrogenic Phenotype and Hyaline Matrix Formation in Human Chondrocytes.Gels (Basel, Switzerland) · 2025Article
- Tooth-on-a-chip to engineer early dental epithelial-mesenchymal interaction.Materials today. Bio · 2025Article
- Temporal transcriptomic profiling of human three-dimensional neuromuscular co-cultures.Biology open · 2025Article
- Neuro-Immunomodulatory Potential of Nanoenabled 4D Bioprinted Microtissue for Cartilage Tissue Engineering.Advanced healthcare materials · 2025Article
- Fabrication of heart tubes from iPSC derived cardiomyocytes and human fibrinogen by rotating mold technology.Scientific reports · 2024Article
- Chitosan-Polyethylene Glycol Inspired Polyelectrolyte Complex Hydrogel Templates Favoring NEO-Tissue Formation for Cardiac Tissue Engineering.Gels (Basel, Switzerland) · 2024Article
- Bioactive Endodontic Hydrogels: From Parameters to Personalized Medicine.International journal of molecular sciences · 2023Review
- Fibrin gel enhanced trilayer structure in cell-cultured constructs.Biotechnology and bioengineering · 2023Article
- Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy.Frontiers in chemistry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In tissue engineering, cell origin is important to ensure outcome quality. However, the impact of the cell type chosen for seeding in a biocompatible matrix has been less investigated. Here, we investigated the capacity of primary and immortalized fibroblasts of distinct origins to degrade a gelatin/alginate/fibrin (GAF)-based biomaterial. We further established that fibrin was targeted by degradative fibroblasts through the secretion of fibrinolytic matrix-metalloproteinases (MMPs) and urokinase, two types of serine protease. Finally, we demonstrated that besides aprotinin, specific targeting of fibrinolytic MMPs and urokinase led to cell-laden GAF stability for at least forty-eight hours. These results support the use of specific strategies to tune fibrin-based biomaterials degradation over time. It emphasizes the need to choose the right cell type and further bring targeted solutions to avoid the degradation of fibrin-containing hydrogels or bioinks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.